Free Trial

Iovance Biotherapeutics (IOVA) Competitors

Iovance Biotherapeutics logo
$2.23 -0.11 (-4.70%)
Closing price 04:00 PM Eastern
Extended Trading
$2.24 +0.00 (+0.22%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IOVA vs. APLS, NAMS, TWST, DNLI, KNSA, AGIO, VCEL, RXRX, CGON, and BEAM

Should you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include Apellis Pharmaceuticals (APLS), NewAmsterdam Pharma (NAMS), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), Agios Pharmaceuticals (AGIO), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), CG Oncology (CGON), and Beam Therapeutics (BEAM). These companies are all part of the "pharmaceutical products" industry.

Iovance Biotherapeutics vs. Its Competitors

Iovance Biotherapeutics (NASDAQ:IOVA) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Apellis Pharmaceuticals has higher revenue and earnings than Iovance Biotherapeutics. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Iovance Biotherapeutics$164.07M4.54-$372.18M-$1.24-1.80
Apellis Pharmaceuticals$781.37M3.13-$197.88M-$1.79-10.88

Iovance Biotherapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.

Iovance Biotherapeutics presently has a consensus price target of $12.22, suggesting a potential upside of 448.08%. Apellis Pharmaceuticals has a consensus price target of $40.00, suggesting a potential upside of 105.44%. Given Iovance Biotherapeutics' higher possible upside, equities analysts clearly believe Iovance Biotherapeutics is more favorable than Apellis Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Iovance Biotherapeutics
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33
Apellis Pharmaceuticals
0 Sell rating(s)
9 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.62

In the previous week, Iovance Biotherapeutics had 11 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 34 mentions for Iovance Biotherapeutics and 23 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.86 beat Iovance Biotherapeutics' score of 0.24 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Iovance Biotherapeutics
4 Very Positive mention(s)
5 Positive mention(s)
21 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Apellis Pharmaceuticals
6 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 10.3% of Iovance Biotherapeutics shares are owned by company insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Apellis Pharmaceuticals has a net margin of -28.83% compared to Iovance Biotherapeutics' net margin of -176.49%. Iovance Biotherapeutics' return on equity of -49.71% beat Apellis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Iovance Biotherapeutics-176.49% -49.71% -39.18%
Apellis Pharmaceuticals -28.83%-99.19%-25.35%

Summary

Apellis Pharmaceuticals beats Iovance Biotherapeutics on 9 of the 17 factors compared between the two stocks.

Get Iovance Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IOVA vs. The Competition

MetricIovance BiotherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$781.41M$2.96B$5.54B$9.41B
Dividend YieldN/A2.46%3.75%4.03%
P/E Ratio-1.808.2821.0120.09
Price / Sales4.54303.17433.8199.01
Price / CashN/A42.5936.1658.27
Price / Book0.967.678.125.65
Net Income-$372.18M-$55.28M$3.25B$257.91M
7 Day Performance19.25%2.50%0.97%2.09%
1 Month Performance9.31%11.70%7.36%11.13%
1 Year Performance-73.16%4.89%31.31%18.40%

Iovance Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IOVA
Iovance Biotherapeutics
4.7457 of 5 stars
$2.23
-4.7%
$12.22
+448.1%
-73.8%$781.41M$164.07M-1.80500Analyst Downgrade
Analyst Revision
Gap Up
APLS
Apellis Pharmaceuticals
4.3305 of 5 stars
$17.41
-4.7%
$39.79
+128.5%
-49.3%$2.19B$781.37M-9.73770Trending News
Analyst Forecast
Insider Trade
Analyst Revision
NAMS
NewAmsterdam Pharma
3.5952 of 5 stars
$19.48
-1.9%
$42.89
+120.2%
+16.9%$2.19B$45.56M-10.364News Coverage
Analyst Forecast
Insider Trade
TWST
Twist Bioscience
4.227 of 5 stars
$35.54
-6.9%
$50.40
+41.8%
-36.2%$2.13B$312.97M-10.94990News Coverage
DNLI
Denali Therapeutics
4.537 of 5 stars
$14.27
-2.9%
$33.71
+136.3%
-36.9%$2.07B$330.53M-5.34430
KNSA
Kiniksa Pharmaceuticals International
3.3535 of 5 stars
$28.12
+0.9%
$38.80
+38.0%
+34.7%$2.05B$481.17M-112.48220Upcoming Earnings
Insider Trade
AGIO
Agios Pharmaceuticals
4.409 of 5 stars
$35.27
-2.2%
$58.60
+66.1%
-14.4%$2.04B$36.50M3.14390
VCEL
Vericel
3.6832 of 5 stars
$39.65
-5.0%
$61.14
+54.2%
-29.9%$2.00B$237.22M1,322.11300News Coverage
Positive News
RXRX
Recursion Pharmaceuticals
1.1335 of 5 stars
$4.91
-6.8%
$7.00
+42.6%
-33.9%$2.00B$58.84M-2.77400Gap Up
High Trading Volume
CGON
CG Oncology
2.531 of 5 stars
$26.18
-2.7%
$58.67
+124.1%
-25.5%$2.00B$662K-17.3461News Coverage
Analyst Forecast
BEAM
Beam Therapeutics
2.0658 of 5 stars
$19.18
-4.1%
$48.75
+154.2%
-24.1%$1.93B$63.52M-4.16510Gap Up

Related Companies and Tools


This page (NASDAQ:IOVA) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners